Gene transfer for ocular neovascularization and macular edema

Gene Therapy

Volumn 19, Issue 2, 2012, Pages 121-126

  Campochiaro, P A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

age related macular degeneration; angiogenesis; diabetic retinopathy; neovascularization; proliferative retinopathies

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CYTOMEGALOVIRUS VECTOR; ENDOSTATIN; FLT 1 FC FRAGMENT CONJUGATE; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; RECOMBINANT VASOHIBIN 1; RESPIRATORY SYNCYTIAL VIRUS VECTOR; RETINOSTAT; SU 4312; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VIRUS VECTOR;

DEVELOPED COUNTRY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; EYE INFLAMMATION; HUMAN; LOW DRUG DOSE; MOLECULAR PATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINOPATHY; REVIEW; SUBRETINAL NEOVASCULARIZATION; TRANSGENE; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; ENDOSTATINS; EYE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MACULAR EDEMA; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 84856954338     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.164     Document Type: Review

References (78)

1. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520-526. (Pubitemid 14127838)
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-943.
3. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41: 3158-3164.
4. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997; 151: 281-291.
5. Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter JS et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21: 416-434. (Pubitemid 32971350)
6. Oshima Y, Oshima S, Nambu H, Kachi S, Hackett SF, Melia M et al. Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol 2004; 201: 393-400. (Pubitemid 39453125)
7. Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 1998; 153: 1641-1646. (Pubitemid 28509922)
8. Yamada H, Yamada E, Kwak N, Ando A, Suzuki A, Esumi N et al. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. J Cell Physiol 2000; 185: 135-142.
9. Saishin Y, Saishin Y, Takahashi K, Lima Silva R, Hylton D, Rudge J et al. VEGFTRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003; 195: 241-248. (Pubitemid 36384298)
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
11. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med 2006; 355: 1432-1444. (Pubitemid 44511558)
12. Ozaki H, Yu A, Della N, Ozaki K, Luna JD, Yamada H et al. Hypoxia inducible factor-1a is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999; 40: 182-189. (Pubitemid 29029587)
13. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003; 93: 1074-1081. (Pubitemid 37485038)
14. Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol 2004; 199: 412-417. (Pubitemid 38580437)
15. Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N et al. Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive. FASEB J 2005; 19: 963-965. (Pubitemid 40827718)
16. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461.
17. Seo M-S, Kwak N, Ozaki H, Yamada H, Okamoto N, Fabbro D et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 1999; 154: 1743-1753. (Pubitemid 29262856)
18. Ozaki H, Seo M-S, Ozaki K, Yamada H, Yamada E, Hofmann F et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000; 156: 679-707.
19. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969.
20. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 2009; 116: 2175-2181.
21. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV et al. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
22. Network TDRCR. Randomized trial evaluating ranibzumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmolgy 2010; 117: 1064-1077.
23. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV et al. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther 2008; 16: 791-799. (Pubitemid 351426182)
24. Campochiaro PA, Hafiz G, Channa R, Shah SM, Nguyen QD, Ying H et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusion: two-year outcomes. Ophthalmology 2010; 117: 2387-2394.
25. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology 2010; 117: 1102-1112.
26. Brown DM, Campochiaro PA, Singh RP, Gray S, Rundle AC, Li Z et al. Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion:6-month results of the phase III CRUISE study. Ophthalmology 2010; 117: 1124-1133.
27. Kendall RL, Wang GL, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Comm 1996; 226: 324-328. (Pubitemid 26331903)
28. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999; 13: 537-545. (Pubitemid 30636421)
29. Tombran-Tink J, Chader GG, Johnson SV. PEDF: a pigment epithelium derived factor with potent neuronal differentiating activity. Exp Eye Res 1991; 53: 411-414.
30. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H-J, Benedict W et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248. (Pubitemid 29329995)
31. O'Reilly MS, Holmgren S, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328. (Pubitemid 24324921)
32. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285. (Pubitemid 28015876)
33. Della NG, Campochiaro PA, Zack DJ. Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1996; 37: 1921-1924. (Pubitemid 26265045)
34. Kamei M, Hollyfield JG. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci 1999; 40: 2367-2375. (Pubitemid 29418393)
35. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995; 270: 14313-14318.
36. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004; 114: 898-907. (Pubitemid 39578717)
37. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member or the serine protease inhibitor gene family. Proc Natl Acad Sci USA 1993; 90: 1526-1530. (Pubitemid 23058206)
38. Araki T, Taniwaki T, Becerra SP, Chader GJ, Schwartz JP. Pigment epithelium-derived factor (PEDF) differentially protects immature but not mature cerebellar granule cells against apoptotic cell death. J Neurosci Res 1998; 53: 7-15. (Pubitemid 28308977)
39. Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl RW. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamatemediated neurodegeneration. J Neuropathol Exp Neurol 1999; 58: 719-728. (Pubitemid 29328501)
40. Cao W, Tombran-Tink J, Elias R, Sezate S, Mrazek D, McGinnis JF. In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2001; 42: 1642-1652.
41. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001; 188: 253-263. (Pubitemid 32622916)
42. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization by increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2001; 43: 2428-2434.
43. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43: 1994-2000. (Pubitemid 34587052)
44. Auricchio A, Behling KC, Maguire AM, O'Conner EM, Bennett J, Wilson JM et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002; 6: 490-494. (Pubitemid 35214870)
45. Raisler BJ, Berns KI, Grant MB, Beliaev D, Hauswirth WW. Adeno-associated virus type 2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002; 99: 8909-8914. (Pubitemid 34693657)
46. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Duh EJ, Yang HS et al. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther 2003; 10: 637-646. (Pubitemid 36553609)
47. Demetriades AM, Deering T, Liu H, Lu L, Gehlbach P, Packer JD et al. Trans-scleral delivery of antiangiogenic proteins. J Ocul Pharmacol Ther 2008; 24: 70-79. (Pubitemid 351156635)
48. Saishin Y, Lima Silva R, Saishin Y, Callahan K, Schoch C, Ahlheim M et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003; 44: 4989-4993. (Pubitemid 37315317)
49. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular agerelated macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17: 167-176. (Pubitemid 43262032)
50. Honda M, Sakamoto T, Ishibashi T, Inomata H, Ueno H. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF.flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 2000; 7: 978-985. (Pubitemid 30386663)
51. Rota R, Riccioni T, Zaccarini M, Lamartina S, Gallo AD, Fusco A et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 2004; 6: 992-1002. (Pubitemid 40228114)
52. Bainbridge J, Mistry A, Alwis MD, Paleolog E, Baker A, Thrasher AJ et al. Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002; 9: 320-326. (Pubitemid 34285145)
53. Lai CM, Shen WY, Brankov M, Lai YK, Barnett NL, Lee SY et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 2005; 12: 659-668. (Pubitemid 41350147)
54. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virusmediated secretion gene therapy. Gene Ther 2002; 9: 804-813. (Pubitemid 34679308)
55. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and VEGF-induced breakdown of the blood-retinal barrier. Hum Gene Ther 2003; 14: 129-141. (Pubitemid 36422598)
56. Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 2009; 16: 10-16.
57. Lukason M, Dufresne E, Hillard R, Pechan P, Li Q, Kim I et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressin a novel anti-VEGF molecule. Mol Ther 2011; 19: 260-265.
58. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171: 53-67. (Pubitemid 47339226)
59. Saint-Geniez M, Raharaj ASR, Walshe TE, Tucker BA, Sekiyama E, , Kurihara T et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. Plos One 2008; 3: e3554: 3551-3511.
60. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 2009; 106: 18751-18756.
61. Ueno S, Pease ME, Wersinger DMB, Masuda T, Vinores SA, Licht T et al. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 2008; 217: 13-22.
62. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703. (Pubitemid 47268059)
63. Miki A, Ueno S, Wesinger DM, Berlinicke C, Shaw GC, Usui S et al. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. J Cell Physiol 2010; 224: 262-272.
64. Maclachian TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C et al. Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Mol Ther 2011; 19: 326-334.
65. Fukai N, Eklund L, Marneros AG, Oh SP, Keene DR, Tamarkin L et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 2002; 21: 1535-1544. (Pubitemid 34614610)
66. Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001; 159: 313-320. (Pubitemid 33704216)
67. Takahashi K, Saishin Y, Saishin Y, Lima Silva R, Oshima Y, Oshima S et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J 2003; 17: 896-898.
68. Ohno-Matsui K, Hirose A, Yamamoto S, Saikia J, Okamoto N, Gehlbach P et al. Inducible expression of vascular endothelial growth factor in photoreceptors of adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol 2002; 160: 711-719. (Pubitemid 34160349)
69. Lai C-C, Wu W-C, Chen S-L, Xiao X, Tsai T-C, Huan S-J et al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 2001; 42: 2401-2407. (Pubitemid 32848872)
70. Igarashi T, Miyake K, Kato K, Watanabe A, Ishizaki M, Ohara K et al. Lentivirusmediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther 2003; 10: 219-226. (Pubitemid 36204410)
71. Balaggan KS, Binley K, Esapa M, MacLaren RE, Iqball S, Duran Y et al. EIAV vectormediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. Gene Ther 2006; 13: 1153-1165. (Pubitemid 44084074)
72. Kachi S, Binley K, Yokoi K, Umeda N, Akiyama H, Muramatu D et al. EIAV vectormediated co-delivery of endostatin and angiostatin driven by the RPE-specific VMD2 promoter inhibits choroidal neovascularization. Hum Gene Ther 2009; 20: 31-39.
73. Weber BHF, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994; 8: 352-356. (Pubitemid 24375600)
74. Soboleva G, Geis B, Schrewe H, Weber BHF. Sorsby fundus dystrophy mutation Timp3s156C affects the morphological and biochemical phenotype but not metalloproteinase homeostasis. J Cell Physiol 2003; 197: 149-156. (Pubitemid 37486237)
75. Fariss RN, Apte SS, Suthert PJ, Bird AC, Milam AH. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br J Ophthalmol 1998; 82: 1329-1334. (Pubitemid 28524133)
76. Takahashi T, Nakamura T, Hayashi A, Kamei M, Nakabayashi M, Okada AA et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium. Am J Ophthalmol 2000; 130: 774-781. (Pubitemid 32000859)
77. Shimizu K, Watanabe K, Yamashita H, Abe M, Yoshimatsu H, Ohta H et al. Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem Biophys Res Comm 2005; 327: 700-706. (Pubitemid 40092806)
78. Shen J, Yang XR, Xiao WH, Hackett SF, Sato Y, Campochiaro PA. Vasohibin is upregulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J 2006; 20: 723-725. (Pubitemid 46671194)